{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:04:48Z","timestamp":1777399488912,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T00:00:00Z","timestamp":1601856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EClinicalMedicine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.eclinm.2020.100601","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T06:57:52Z","timestamp":1602831472000},"page":"100601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Risk of hepatitis B reactivation and cytomegalovirus related infections with Mogamulizumab: A retrospective study of international pharmacovigilance database"],"prefix":"10.1016","volume":"28","author":[{"given":"Shuai","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apoorva","family":"Jayarangaiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariuxi","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Elrafei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9617-3579","authenticated-orcid":false,"given":"Abhishek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2020.100601_bib0001","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984\u201387)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eclinm.2020.100601_bib0002","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2020.100601_bib0003","doi-asserted-by":"crossref","unstructured":"Jacobsen ED and Weinstock DM, 2018. Challenges and implications of genomics for T-cell lymphomas. Hematology 2014, the American Society of Hematology Education Program Book, 2018(1), pp. 63\u201368.","DOI":"10.1182\/asheducation-2018.1.63"},{"key":"10.1016\/j.eclinm.2020.100601_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.01062","article-title":"Novel treatments of adult T cell leukemia lymphoma","volume":"11","author":"El Hajj","year":"2020","journal-title":"Front Microbiol"},{"issue":"7","key":"10.1016\/j.eclinm.2020.100601_bib0005","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1182\/blood-2011-03-345702","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"118","author":"Bazarbachi","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.eclinm.2020.100601_bib0006","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2020.100601_bib0007","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40259-017-0223-8","article-title":"Improving antibody-based cancer therapeutics through glycan engineering","volume":"31","author":"Yu","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.eclinm.2020.100601_bib0008","unstructured":"Press announcements-FDA approves treatment for two rare types of non-Hodgkin lymphom (Last access date: july 29,2020) https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-two-rare-types-non-hodgkin-lymphoma."},{"issue":"8","key":"10.1016\/j.eclinm.2020.100601_bib0009","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2020.100601_bib0010","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2020.100601_bib0011","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T\u2010cell leukaemia\u2010lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.eclinm.2020.100601_bib0012","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/hepr.12513","article-title":"Fatal reactivation of hepatitis B virus infection in a patient with adult T\u2010cell leukemia\u2013lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab","volume":"45","author":"Ifuku","year":"2015","journal-title":"Hepatol Res"},{"issue":"4","key":"10.1016\/j.eclinm.2020.100601_bib0013","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12185-017-2270-9","article-title":"Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia\u2013lymphoma in Japan: interim results of post-marketing all-case surveillance","volume":"106","author":"Ishitsuka","year":"2017","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.eclinm.2020.100601_bib0014","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2169\/internalmedicine.55.5644","article-title":"Cytomegalovirus pneumonia after anti-CC-chemokine receptor 4 monoclonal antibody (mogamulizumab) therapy in an angioimmunoblastic T-cell lymphoma patient","volume":"55","author":"Ishii","year":"2016","journal-title":"Internal Med"},{"key":"10.1016\/j.eclinm.2020.100601_bib0015","unstructured":"United States Food and Drug Administration. FDA Adverse Reporting System Public Dashboard (Last access date: july 29, 2020), https:\/\/fis.fda.gov\/sense\/app\/d10be6bb-494e-4cd2-82e4-0135608ddc13\/sheet\/33a0f68e-845c-48e2-bc81-8141c6aaf772\/state\/analysis."},{"issue":"21","key":"10.1016\/j.eclinm.2020.100601_bib0016","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1001\/jama.1993.03500210065033","article-title":"Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems","volume":"269","author":"Kessler","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2020.100601_bib0017","unstructured":"Medical Dictionary for Regulatory Activities. (last accessed on Jul 27,2020) https:\/\/www.meddra.org\/"},{"issue":"6","key":"10.1016\/j.eclinm.2020.100601_bib0018","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.eclinm.2020.100601_bib0019","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1046\/j.0306-5251.2001.01501.x","article-title":"Determinants of signal selection in a spontaneous reporting system for adverse drug reactions","volume":"52","author":"Van Puijenbroek","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.eclinm.2020.100601_bib0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.hemonc.2016.04.004","article-title":"Disseminated Mycobacterium chelonae infection in a patient with T-cell lymphoma","volume":"10","author":"van der Wekken","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"10","key":"10.1016\/j.eclinm.2020.100601_bib0021","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.eclinm.2020.100601_bib0022","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/intimm\/11.1.81","article-title":"Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine","volume":"11","author":"Imai","year":"1999","journal-title":"Int Immunol"},{"key":"10.1016\/j.eclinm.2020.100601_bib0023","unstructured":"ClinicalTrials.gov (last accessed on May 16,2020) https:\/\/clinicaltrials.gov\/ct2\/results?cond=mogamulizumab&term=&cntry=&state=&city=&dist="},{"issue":"22","key":"10.1016\/j.eclinm.2020.100601_bib0024","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-19-1090","article-title":"A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors","volume":"25","author":"Doi","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.eclinm.2020.100601_bib0025","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa1704827","article-title":"Mogamulizumab (Anti-CCR4) in HTLV-1\u2013associated myelopathy","volume":"378","author":"Sato","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.eclinm.2020.100601_bib0026","doi-asserted-by":"crossref","first-page":"398e404","DOI":"10.1007\/s12185-015-1750-z","article-title":"Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy","volume":"101","author":"Totani","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.eclinm.2020.100601_bib0027","doi-asserted-by":"crossref","first-page":"354e7","DOI":"10.1111\/hepr.12117","article-title":"Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab","volume":"44","author":"Nakano","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.eclinm.2020.100601_bib0028","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdj132","article-title":"Antiviral prophylaxis in patients with haematological malignancies and solid tumours: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO)","volume":"17","author":"Sandherr","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2020.100601_bib0029","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID study group for infections in compromised hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.eclinm.2020.100601_bib0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"10.1016\/j.eclinm.2020.100601_bib0031","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/10428194.2013.798867","article-title":"Cytomegalovirus infection and end-organ disease in Asian patients with lymphoma receiving chemotherapy","volume":"55","author":"Tay","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.eclinm.2020.100601_bib0032","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3816\/CLM.2006.n.016","article-title":"Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality","volume":"6","author":"Torres","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"11","key":"10.1016\/j.eclinm.2020.100601_bib0033","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.eclinm.2020.100601_bib0034","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","article-title":"Rituximab-related viral infections in lymphoma patients","volume":"48","author":"Aksoy","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.eclinm.2020.100601_bib0035","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1872-034X.2012.00998.x","article-title":"Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy","volume":"42","author":"Oketani","year":"2012","journal-title":"Hepatol Res"},{"issue":"7","key":"10.1016\/j.eclinm.2020.100601_bib0036","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","article-title":"Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy","volume":"148","author":"Loomba","year":"2008","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.eclinm.2020.100601_bib0037","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"Management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.eclinm.2020.100601_bib0038","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"}],"container-title":["EClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702030345X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702030345X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:02:21Z","timestamp":1762887741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258953702030345X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":38,"alternative-id":["S258953702030345X"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2020.100601","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of hepatitis B reactivation and cytomegalovirus related infections with Mogamulizumab: A retrospective study of international pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"EClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2020.100601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100601"}}